We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Hits Sarepta With Complete Response Letter for Duchenne Drug
FDA Hits Sarepta With Complete Response Letter for Duchenne Drug
Sarepta Therapeutics was “surprised” to receive a complete response letter from the FDA for its new drug application for Vydonos 53 (golodirsen) for treatment of Duchenne muscular dystrophy.